New Uricosuric Agent in the Treatment of Gout: Para-Carboxybenzenesulpha-Diethylamide (Urelim)

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/ard.19.4.356
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

The Present Status of Colchicine and Uricosuric Agents in Management of Primary Gout

Arthritis & Rheumatism
1965English

Pms55 - The Effects of Mortality Assumptions on the Cost Effectiveness of a New Gout Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Impact of the Illness Label ‘Gout’ on Illness and Treatment Perceptions in Māori (Indigenous New Zealanders)

BMC Rheumatology
Rheumatology
2020English

Benefit Restrictions and Gout Treatment

Journal of Managed Care Pharmacy
2013English

Long-Term Use of Allopurinol in the Treatment of Gout.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1970English

Intermittent Control of Hyperuricemia in the Treatment of Gout: 186

Pediatric Research
Child HealthPediatricsPerinatology
1985English

Treatment of Gout in Patients After Organ Transplantation

Reumatologia
RheumatologyAllergyImmunology
2013English

Lysergic Acid Diethylamide

BMJ
1966English

Factors Affecting Treatment Discontinuation in Patients With Gout

GOUT AND NUCLEIC ACID METABOLISM
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy